140 related articles for article (PubMed ID: 26608382)
1. Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers.
Chen SM; Atchley DH; Murphy MA; Gurley BJ; Kamdem LK
J Clin Pharmacol; 2016 Jul; 56(7):875-84. PubMed ID: 26608382
[TBL] [Abstract][Full Text] [Related]
2. Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.
Chanawong A; Mackenzie PI; McKinnon RA; Hu DG; Meech R
J Pharmacol Exp Ther; 2017 Jun; 361(3):482-491. PubMed ID: 28404691
[TBL] [Abstract][Full Text] [Related]
3. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.
Sun D; Chen G; Dellinger RW; Sharma AK; Lazarus P
Pharmacogenet Genomics; 2010 Oct; 20(10):575-85. PubMed ID: 20697310
[TBL] [Abstract][Full Text] [Related]
4. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Kamdem LK; Xi J; Clark BL; Gregory BJ; Kidwell KM; Storniolo AM; Stearns V; Hayes DF; Gersch CL; Rae JM; Henry NL; Hertz DL
Breast Cancer Res Treat; 2019 Jun; 175(2):297-303. PubMed ID: 30747308
[TBL] [Abstract][Full Text] [Related]
5. Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers.
Gregory BJ; Chen SM; Murphy MA; Atchley DH; Kamdem LK
J Clin Pharm Ther; 2017 Oct; 42(5):547-553. PubMed ID: 28868654
[TBL] [Abstract][Full Text] [Related]
6. Role of the UGT2B17 deletion in exemestane pharmacogenetics.
Luo S; Chen G; Truica C; Baird CC; Leitzel K; Lazarus P
Pharmacogenomics J; 2018 Apr; 18(2):295-300. PubMed ID: 28534527
[TBL] [Abstract][Full Text] [Related]
7. Effect of Aromatase Inhibition (Exemestane) on Urine Concentration of Osteoprotegerin in Healthy Postmenopausal Women.
Garcia AP; Hatvany JB; Murphy MA; Atchley DH; Gurley BJ; Kamdem LK
J Clin Pharmacol; 2020 Feb; 60(2):209-217. PubMed ID: 31535401
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.
Johansson H; Aristarco V; Gandini S; Gjerde J; Macis D; Guerrieri-Gonzaga A; Serrano D; Lazzeroni M; Rajasekaran A; Williard CV; Mellgren G; DeCensi A; Bonanni B
Pharmacogenomics J; 2020 Feb; 20(1):19-26. PubMed ID: 30967597
[TBL] [Abstract][Full Text] [Related]
9. Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial.
Ho V; Pasquet R; Luo S; Chen G; Goss P; Tu D; Lazarus P; Richardson H;
Breast Cancer Res Treat; 2020 Oct; 183(3):705-716. PubMed ID: 32715442
[TBL] [Abstract][Full Text] [Related]
10. Effect of UGT2B17 deletion polymorphism on prognosis in pediatric cancer.
Ishimaru S; Yuza Y; Kaneko T; Urashima M
Pediatr Int; 2017 Apr; 59(4):427-431. PubMed ID: 27805301
[TBL] [Abstract][Full Text] [Related]
11. The UGT2B17 gene deletion is not associated with prostate cancer risk.
Olsson M; Lindström S; Häggkvist B; Adami HO; Bälter K; Stattin P; Ask B; Rane A; Ekström L; Grönberg H
Prostate; 2008 Apr; 68(5):571-5. PubMed ID: 18247404
[TBL] [Abstract][Full Text] [Related]
12. COX2 induction: a mechanism of endocrine breast cancer resistance?
Clark BL; Murphy MA; Kamdem LK
Breast Cancer Res Treat; 2017 Sep; 165(2):383-389. PubMed ID: 28639029
[TBL] [Abstract][Full Text] [Related]
13. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate.
Karypidis AH; Olsson M; Andersson SO; Rane A; Ekström L
Pharmacogenomics J; 2008 Apr; 8(2):147-51. PubMed ID: 17387331
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex.
Bhatt DK; Basit A; Zhang H; Gaedigk A; Lee SB; Claw KG; Mehrotra A; Chaudhry AS; Pearce RE; Gaedigk R; Broeckel U; Thornton TA; Nickerson DA; Schuetz EG; Amory JK; Leeder JS; Prasad B
Drug Metab Dispos; 2018 Jun; 46(6):888-896. PubMed ID: 29602798
[TBL] [Abstract][Full Text] [Related]
15. The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians.
Gallagher CJ; Kadlubar FF; Muscat JE; Ambrosone CB; Lang NP; Lazarus P
Cancer Detect Prev; 2007; 31(4):310-5. PubMed ID: 17935910
[TBL] [Abstract][Full Text] [Related]
16. Increased severity of acute graft versus host disease as a result of differential expression following a homozygous gene deletion.
Jervis S; Collins P; Tate D; Foster L; Bowman V; Adhern C; Bloor A; Yin J; Wynn R; Poulton K
Int J Immunogenet; 2013 Apr; 40(2):116-9. PubMed ID: 22726315
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological investigation of the UGT2B17 polymorphism in doping control urine samples and its correlation to T/E ratios.
Anielski P; Simmchen J; Wassill L; Ganghofner D; Thieme D
Drug Test Anal; 2011 Oct; 3(10):645-51. PubMed ID: 21928278
[TBL] [Abstract][Full Text] [Related]
18. Homozygous deletion of the UGT2B17 gene is not associated with osteoporosis risk in elderly Caucasian women.
Chew S; Mullin BH; Lewis JR; Spector TD; Prince RL; Wilson SG
Osteoporos Int; 2011 Jun; 22(6):1981-6. PubMed ID: 20878390
[TBL] [Abstract][Full Text] [Related]
19. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.
Park J; Chen L; Ratnashinge L; Sellers TA; Tanner JP; Lee JH; Dossett N; Lang N; Kadlubar FF; Ambrosone CB; Zachariah B; Heysek RV; Patterson S; Pow-Sang J
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1473-8. PubMed ID: 16896035
[TBL] [Abstract][Full Text] [Related]
20. A common deletion in the uridine diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong determinant of androgen excretion in healthy pubertal boys.
Juul A; Sørensen K; Aksglaede L; Garn I; Rajpert-De Meyts E; Hullstein I; Hemmersbach P; Ottesen AM
J Clin Endocrinol Metab; 2009 Mar; 94(3):1005-11. PubMed ID: 19088161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
